Clover Health (CLOV) director gets 79,365 RSUs vesting in 2027 shares

Rhea-AI Filing Summary

Clover Health Investments, Corp. reported that director Demetrios L. Kouzoukas received an equity award in the form of restricted stock units. On January 6, 2026, he acquired 79,365 shares of Class A common stock at a price of $0 per share, reflecting the grant of time-based RSUs rather than a cash purchase.

These RSUs represent shares that will vest in full on the first anniversary of January 6, 2026, as long as he continues to serve as a director through that vesting date. After this grant, Kouzoukas beneficially owned 605,980 shares of Class A common stock, held directly.

Insider Trade Summary

Net Buyer: 79,365 shares

Net Buy 1 txn

Insider Kouzoukas Demetrios L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	79,365	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 605,980 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Class A Common Stock underlying an award of time-based restricted stock units (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2026, subject to the Reporting Person's continued service as a director through such vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/08/2026 - 04:20 PM Learn about SEC filing dates

FAQ

What insider transaction did CLOV disclose for Demetrios L. Kouzoukas?

Clover Health Investments, Corp. disclosed that director Demetrios L. Kouzoukas was granted 79,365 shares of Class A common stock via restricted stock units on January 6, 2026.

Were the CLOV shares acquired by the director purchased with cash?

No. The 79,365 shares reported for Demetrios L. Kouzoukas were granted at $0 per share as part of a restricted stock unit (RSU) award, not bought in the open market.

When do the CLOV restricted stock units granted to Demetrios L. Kouzoukas vest?

The RSUs granted to Demetrios L. Kouzoukas will vest in full on the first anniversary of January 6, 2026, if he continues serving as a director through that date.

How many CLOV shares does Demetrios L. Kouzoukas own after this transaction?

Following the reported RSU grant, Demetrios L. Kouzoukas beneficially owned 605,980 shares of Class A common stock of Clover Health Investments, Corp., held directly.

What is the nature of the CLOV equity award reported for the director?

The award to Demetrios L. Kouzoukas consists of time-based restricted stock units (RSUs) that convert into Class A common shares upon vesting, subject to his continued service as a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kouzoukas Demetrios L.

(Last) (First) (Middle)

C/O CLOVER HEALTH INVESTMENTS, CORP.

NOT APPLICABLE

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	01/06/2026		A		79,365(1)	A	$0	605,980	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Class A Common Stock underlying an award of time-based restricted stock units (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2026, subject to the Reporting Person's continued service as a director through such vesting date.

Remarks:

	/s/Peter J. Rivas as attorney-in-fact for Demetrios L. Kouzoukas	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.